ArticleFood science & nutrition2025
Safety Evaluation of Ultrasonic-Assisted OSA-Modified Tamarind Seed Gum for Food Applications.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety Evaluation of Ultrasonic-Assisted OSA-Modified Tamarind Seed Gum for Food Applications.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evaluating the safety profile of substances used in food products is essential. Ultrasonic-assisted octenyl succinic acid-modified tamarind seed gum (OSA-TSG) has shown potential as an emulsifier and stabilizer in a variety of food applications; however, its safety profile has not yet been thoroughly investigated. In the present study, the acute oral toxicity of both pure tamarind seed gum (TSG) and ultrasonic-assisted OSA-TSG was evaluated in Sprague Dawley rats over 21 days. The purpose of the study was to assess the safety of these gums with respect to potential adverse effects and mortality following a single oral dose of 300 and 2000 mg/kg body weight. Body weight and feed intake were monitored at 0 and 21 days, respectively, and significant effects were observed in the TSG and ultrasonic-assisted OSA-TSG-treated groups compared to the control group. No adverse effects were seen in hematological and biochemical parameters in either treatment group. Furthermore, no macroscopic or histological alterations were found in vital organs (heart, brain, liver, and kidney) upon necropsy that could be attributed to the administration of test substances. In conclusion, both pure and ultrasonic-assisted OSA-TSG exhibited an LD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.